LXEO
Price
$3.10
Change
+$0.04 (+1.31%)
Updated
Nov 3, 04:03 PM (EDT)
Capitalization
251.19M
One day until earnings call
Intraday BUY SELL Signals
RLAY
Price
$17.62
Change
+$0.34 (+1.97%)
Updated
Nov 3, 04:10 PM (EDT)
Capitalization
3.79B
2 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LXEO vs RLAY

LXEO vs RLAY Comparison Chart in %
View a ticker or compare two or three
VS
LXEO vs. RLAY commentary
Nov 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LXEO is a Hold and RLAY is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for LXEO with price predictions
Nov 02, 2026

LXEO's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for LXEO turned positive on October 20, 2026. Looking at past instances where LXEO's MACD turned positive, the stock continued to rise in 27 of 31 cases over the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where LXEO's RSI Oscillator exited the oversold zone, 9 of 15 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on LXEO as a result. In 40 of 48 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

Following a +15.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where LXEO advanced for three days, in 152 of 180 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

LXEO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 37 cases where LXEO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LXEO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for LXEO entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.069) is normal, around the industry mean (3.104). P/E Ratio (-3.477) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. LXEO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LXEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for RLAY with price predictions
Nov 02, 2026

Momentum Indicator for RLAY turns positive, indicating new upward trend

RLAY saw its Momentum Indicator move above the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 82 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for RLAY just turned positive on October 21, 2026. Looking at past instances where RLAY's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.

The 10-day moving average for RLAY crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.

Following a +8.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where RLAY advanced for three days, in 236 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 52 cases where RLAY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 77%.

RLAY moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

RLAY broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for RLAY entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.255) is normal, around the industry mean (3.104). P/E Ratio (-11.077) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (333.333) is also within normal values, averaging (439.647).

The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. RLAY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
RLAY: Fundamental Ratings
RLAY
OUTLOOK RATING
1..100
65
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
33
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
LXEORLAY
RSI
ODDS (%)
Bullish Trend 2 days ago
60%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 7 days ago
84%
Bullish Trend 7 days ago
86%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
COMPARISON
Comparison
Nov 03, 2026
Stock price -- (LXEO: $3.06 vs. RLAY: $17.28)
Brand notoriety: LXEO and RLAY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LXEO: 86% vs. RLAY: 109%
Market capitalization -- LXEO: $251.19M vs. RLAY: $3.79B
LXEO [@Biotechnology] is valued at $251.19M. RLAY’s [@Biotechnology] market capitalization is $3.79B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $140.2B. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LXEO’s FA Score shows that 1 FA rating(s) are green while RLAY’s FA Score has 2 green FA rating(s).

  • LXEO’s FA Score: 1 green, 4 red.
  • RLAY’s FA Score: 2 green, 3 red.
According to our system of comparison, RLAY is a better buy in the long-term than LXEO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LXEO’s TA Score shows that 5 TA indicator(s) are bullish while RLAY’s TA Score has 4 bullish TA indicator(s).

  • LXEO’s TA Score: 5 bullish, 3 bearish.
  • RLAY’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, LXEO is a better buy in the short-term than RLAY.

Price Growth

LXEO (@Biotechnology) experienced а +13.33% price change this week, while RLAY (@Biotechnology) price change was -4.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.94%. For the same industry, the average monthly price growth was -11.98%, and the average quarterly price growth was -17.06%.

Reported Earning Dates

LXEO is expected to report earnings on Nov 04, 2026.

RLAY is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-1.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
LXEO
Daily Signal:
Gain/Loss:
RLAY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

LXEO and

Correlation & Price change

A.I.dvisor indicates that over the last year, LXEO has been loosely correlated with PRME. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if LXEO jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXEO
1D Price
Change %
LXEO100%
-2.55%
PRME - LXEO
53%
Loosely correlated
-5.93%
SLDB - LXEO
52%
Loosely correlated
-3.23%
KURA - LXEO
51%
Loosely correlated
-4.58%
EDIT - LXEO
51%
Loosely correlated
-3.75%
RCKT - LXEO
50%
Loosely correlated
+1.23%
More

RLAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLAY has been loosely correlated with KURA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RLAY jumps, then KURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLAY
1D Price
Change %
RLAY100%
-5.83%
KURA - RLAY
48%
Loosely correlated
-4.58%
CGEM - RLAY
47%
Loosely correlated
-0.67%
SNDX - RLAY
46%
Loosely correlated
-4.03%
VCYT - RLAY
44%
Loosely correlated
-2.02%
LXEO - RLAY
43%
Loosely correlated
-2.55%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FAS173.228.42
+5.11%
Direxion Daily Financial Bull 3X ETF (FAS)
ERTH41.410.51
+1.24%
Invesco MSCI Sustainable Future ETF (ERTH)
DPRE24.86N/A
N/A
Virtus Duff & Phelps Real Estate Income ETF
BREM48.83-0.21
-0.43%
iShares Emerging Markets Bond Active ETF (BREM)
TSPY24.79-0.13
-0.52%
TappAlpha S&P 500 Growth & Daily Income ETF (TSPY)